3-马来酰亚胺基丙酰肼三氟乙酸盐 | 359436-61-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 3-马来酰亚胺基丙酰肼三氟乙酸盐
• 中文别名: 3-马来酰亚胺丙酸肼三氟乙酸盐
• 英文名称: N-β-maleimidopropionic acid hydrazide trifluoroacetate salt
• 英文别名: BMPH；BMPH (N-(beta-maleimidopropionic acid) hydrazide, trifluoroacetic acid salt)；[3-(2,5-dioxopyrrol-1-yl)propanoylamino]azanium;2,2,2-trifluoroacetate
• CAS: 359436-61-6
• 化学式: C₂HF₃O₂*C₇H₉N₃O₃
• 分子量: 297.191
• InChiKey: BADCXPKRBUEEMA-UHFFFAOYSA-N

物化性质

• 熔点：
  120-123°C
• 溶解度：
  DMF、DMSO、甲醇、水

计算性质

• 辛醇/水分配系数(LogP)：
  -1.08
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  130
• 氢给体数：
  3
• 氢受体数：
  9

安全信息

• 海关编码：
  2928000090
• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319
• 储存条件：
  -20°C

制备方法与用途

有机太阳能电池（OPV）材料

反应信息

• 作为反应物：
  描述：

  羟可待酮 、 3-马来酰亚胺基丙酰肼三氟乙酸盐 在 三氟乙酸 作用下， 以 甲醇 为溶剂， 反应 16.0h， 生成
  参考文献：
  名称：

  通过药物偶联自组装基因编码肽聚合物的热响应纳米颗粒

  摘要：

  按需纳米颗粒：在疏水分子与生物聚合物骨架的一端进行位点特异性共价连接后，嵌合多肽（衍生自弹性蛋白样多肽）可以自组装形成适合药物递送的热响应纳米颗粒。分配系数大于 1.5 的分子赋予足够的两亲性以驱动自组装成亚 100 nm 纳米粒子（见图）。

  DOI：

  10.1002/anie.201200899

文献信息

• 一种多肽桥连的双酰腙连接键应用于醛衍生药物的递送
  申请人：厦门大学

  公开号：CN107029243A

  公开（公告）日：2017-08-11

  一种多肽桥连的双酰腙连接键应用于醛衍生药物的递送，涉及pH响应型双酰腙连接键。该发明涉及一类新的化学连接键，与传统单酰腙键不同，该连接键通过两个酰腙键间的协同稳定作用，使得该类PTA‑linkers在中性(血液循环)或者酸性条件下(肿瘤组织，内含体，溶酶体)都具有超高的稳定性。当桥连双酰腙键的多肽链被特定蛋白酶水解后，两个酰腙键间的协同稳定作用消失，因此在酸性条件又可以具有良好的响应性。以PTA‑linkers作为连接键，设计细胞外和细胞内多肽链定点水解的两种前药分子，两种前药都可以迅速地释放醛衍生药物分子并杀死肿瘤细胞。
• SURFACE BINDING OF NANOPARTICLE BASED DRUG DELIVERY TO TISSUE
  申请人：Massachusetts Institute of Technology

  公开号：US20140193508A1

  公开（公告）日：2014-07-10

  Microparticles and nanoparticles and compositions thereof are provided. The microparticles and nanoparticles and compositions may be used for the treatment of musculoskeletal disease, such as osteoarthritis and injury.

  提供微粒和纳米粒子及其组合物。这些微粒和纳米粒子及其组合物可用于治疗肌肉骨骼疾病，如骨关节炎和损伤。
• [EN] A SINGLE-DOMAIN ANTIBODY FOR TARGETING PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)<br/>[FR] ANTICORPS À DOMAINE UNIQUE POUR LE CIBLAGE D'UN ANTIGÈNE MEMBRANAIRE SPÉCIFIQUE DE LA PROSTATE (PSMA)
  申请人：NAT INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD

  公开号：WO2021038571A8

  公开（公告）日：2022-11-17
• Nanobodies Targeting Prostate-Specific Membrane Antigen for the Imaging and Therapy of Prostate Cancer
  作者：Lior Rosenfeld、Amiram Sananes、Yuval Zur、Shira Cohen、Kalyan Dhara、Sigal Gelkop、Efrat Ben Zeev、Anat Shahar、Leslie Lobel、Barak Akabayov、Eyal Arbely、Niv Papo

  DOI：10.1021/acs.jmedchem.0c00418

  日期：2020.7.23

  The repertoire of methods for the detection and chemotherapeutic treatment of prostate cancer (PCa) is currently limited. Prostate-specific membrane antigen (PSMA) is overexpressed in PCa tumors and can be exploited for both imaging and drug delivery. We developed and characterized four nanobodies that present tight and specific binding and internalization into PSMA+ cells and that accumulate specifically in PSMA(+) tumors. We then conjugated one of these nanobodies to the cytotoxic drug doxorubicin, and we show that the conjugate internalizes specifically into PSMA(+) cells, where the drug is released and induces cytotoxic activity. In vivo studies show that the extent of tumor growth inhibition is similar when mice are treated with commercial doxorubicin and with a 42-fold lower amount of the nanobody-conjugated doxorubicin, attesting to the efficacy of the conjugated drug. These data highlight nanobodies as promising agents for the imaging of PCa tumors and for the targeted delivery of chemotherapeutic drugs.
• Cell-Specific Delivery of a Chemotherapeutic to Lung Cancer Cells
  作者：Xin Zhou、Ya-Ching Chang、Tsukasa Oyama、Michael J. McGuire、Kathlynn C. Brown

  DOI：10.1021/ja0446496

  日期：2004.12.1

  We report that lung cancer-targeting peptides isolated from a peptide library can be used to deliver an active chemotherapeutic in a cell-specific fashion. The peptides were removed from the context of the phage and placed on a pegylated tetrameric scaffold. The tetrameric peptides were shown to block uptake of their cognate phage. The tetrameric peptides were coupled to doxorubicin, and their cytotoxicity against a panel of different cell lines was tested. Our data demonstrate that these targeting peptides can deliver an active anticancer agent in a cell-specific fashion, resulting in an increase of the therapeutic index of the targeted drug compared to systemic delivery. The efficacy of the peptide conjugate correlates to the affinity of the targeting peptide for a particular cell line. As such, we have demonstrated that cell-specific targeted drugs can be synthesized, even when the cell surface target is unknown.